Design, synthesis and antitumor activity of potent and safe para-quinone methides derivatives in vitro and in vivo - 15/11/22
Abstract |
Compounds containing Michael acceptor units display a wide variety of biological effects, and have attracted much attention in medicinal chemistry. In this paper, we designed and synthesized a panel of para-quinone methides (p-QMs) derivatives, classified as electron-deficient alkenes, and evaluated their cytotoxicity against cancer cells. These results revealed that drawing substituents into the ortho-position of the phenyl ring could obviously strengthen the cytotoxicity of p-QMs derivatives compared with that of meta- and para-substituents. Further biological studies demonstrated that the cytotoxicity of p-QMs derivatives originated from their ROS-generation abilities, which could further disrupt the redox balance, lipid peroxidation, the loss of MMP, cell cycle arrest at G0/G1 phase and apoptosis. 1h also exhibited potent antitumor activity through inhibiting TrxR and activating Bax and caspase 3 expression in vitro and in vivo, and 1h had certain safety in vivo. Moreover, the electrophilicity of the Michael acceptor, which could covalently modify with the TrxR, play a potent role in the ROS generation. From the perspective of chemistry, we affirmed that p-QMs derivatives could rapidly covalent binding with cysteamine, and the addition product was characterized by 1H NMR. Together, these new p-QMs derivatives may possess potential as leads for development of effective antitumor agents.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | p-QMs derivatives exhibited moderate to good cytotoxicity on cancer cells. |
• | p-QMs derivatives showed strong electrophilicity and rapidly reacted with cysteamine. |
• | p-QMs derivative 1h displayed potent antitumor activity by inhibiting TrxR in vitro and in vivo. |
• | 1h had certain safety in vivo. |
Keywords : para-Quinone methides, Michael acceptor, Antitumor activity, Reactive oxygen species, Synthesis
Plan
Vol 156
Article 113893- décembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?